1. Home
  2. CLM vs RARE Comparison

CLM vs RARE Comparison

Compare CLM & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.43

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$26.89

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLM
RARE
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.3B
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
CLM
RARE
Price
$7.43
$26.89
Analyst Decision
Strong Buy
Analyst Count
0
20
Target Price
N/A
$59.10
AVG Volume (30 Days)
1.4M
1.5M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.31
EPS
N/A
N/A
Revenue
N/A
$673,000,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$37.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.13
52 Week Low
$6.92
$18.29
52 Week High
$8.53
$39.98

Technical Indicators

Market Signals
Indicator
CLM
RARE
Relative Strength Index (RSI) 40.66 65.07
Support Level $7.33 $21.54
Resistance Level $7.79 $27.42
Average True Range (ATR) 0.11 1.23
MACD -0.02 0.43
Stochastic Oscillator 7.47 85.08

Price Performance

Historical Comparison
CLM
RARE

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: